Bone mineral density in prepubertal children with β-thalassemia: Correlation with growth and hormonal data

Metabolism: Clinical and Experimental

Volumn 47, Issue 5, 1998, Pages 541-548

  Soliman, Ashraf T ^a   El Banna, Nagwa ^b   Fattah, Mohammed Abdel ^b   ElZalabani, Mahmoud M ^b   Ansari, B M ^b  

^a ALEXANDRIA UNIVERSITY   (Egypt)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; CLONIDINE; GLUCAGON; GROWTH HORMONE; INTERLEUKIN 1BETA; PARATHYROID HORMONE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D;

ADOLESCENT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BETA THALASSEMIA; BODY MASS; BONE DENSITY; BONE GROWTH; BONE MINERAL; BONE MINERALIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DIET SUPPLEMENTATION; DIET THERAPY; HUMAN; HYPOCALCEMIA; HYPOPARATHYROIDISM; OSTEOPOROSIS; PATHOLOGIC FRACTURE; PHOTON ABSORPTIOMETRY; PREPUBERTY; PRIORITY JOURNAL; RICKETS; SCHOOL CHILD; SHORT STATURE; SIDEROSIS; THALASSEMIA MAJOR;

EID: 0031948778     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0026-0495(98)90237-2     Document Type: Article

References (102)

1. Heaney RP, Matkovic V: Inadequate peak bone mass, in Riggs BL, Melton LJ (eds): Osteoporosis: Etiology, Diagnosis and Management (ed 2). Philadelphia, PA, Lippincott-Raven, 1995, pp 115-131
2. Bisbocci D, Livorno P, Modina P, et al: Osteodystrophy in thalassemia major. Ann Ital Med Int 8:224-226, 1993
3. Gordon IRS, Ross FGM (eds): Diagnostic Radiology in Pediatrics. London, UK, Butterworths, 1977
4. Giardina P: Osteoporosis in Thalassemia. Proceedings of the London Conference. Oxford, UK, Butterworth-Heinemann, 1990
5. Canatan D, Akar N, Arcasoy A: Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol 93:20-23, 1995
6. Anapliotou ML, Kastanias IT, Psara P: The contribution of hypogonadism to the development of osteoporosis in thalassemia major: New therapeutic approach. Clin Endocrinol (Oxf) 42:279-287, 1995
7. El Hazmi MAF, Warsy AS, Al Fawaz I: Iron-endocrine pattern in patients with β-thalassemia. J Trop Pediatr 40:219-224, 1994
8. Clegg JB, Weatherall DJ: The Thalassemia Syndrome (ed 3). Oxford, UK, Blackwell Scientific 1985, pp 157-190
9. Borgna-Pignatti C, De Stefano P, Zonta L: Growth and sexual maturation in thalassemia major. J Pediatr 106:150-155, 1985
10. Costin G, Kogut MD, Hyman CB, et al: Endocrine abnormalities in thalassemia major. Am J Dis Child 133:497-502, 1979
11. Tanner WW, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty. Arch Dis Child 51:170-179, 1976
12. Greulich WW, Pyle SI (eds): Radiographic Atlas of Skeletal Development of the Hand and Wrist (ed 2). Stanford, CA, Stanford University Press, 1959
13. Ponder SW, McCormik DP, Fawcett D, et al: Spinal bone mineral density in children aged 5.00 through 11.9 years. Am J Dis Child 144:1346-1348, 1990
14. Smith D, Matkovic V, Fontana D, et al: Factors which influence peak bone mass formation: A study of calcium balance and the inheritance of bone mass in adolescent females. Am J Clin Nutr 52:878-888, 1990
15. Glastre C, Braillon P, David L, et al: Measurement of bone mineral content of the lumbar spine by dual energy x-ray absorptiometry in normal children: Correlations with growth parameters. J Clin Endocrinol Metab 70:1330-1333, 1990
16. Bonjour JP, Theintz G, Buchs B, et al: Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 73:555-563, 1991
17. Theintz G, Buchs B, Rizzoli R: Longitudinal monitoring of bone mass accumulation in healthy adolescents: Evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 75:1660-1665, 1992
18. Matkovic V, Jelic T, Wardlaw GM: Timing of peak bone mass in caucasian females and its implication for the prevention of osteoporosis: Inference from cross-sectional model. J Clin Invest 93:799-808, 1994
19. Heaney RP, Matkovic V: Inadequate peak bone mass, in Riggs BL, Melton LJ (eds): Osteoporosis: Etiology, Diagnosis, and Management (ed 2). Philadelphia, PA, Lippincott-Raven, 1995, pp 115-310
20. Matkovic V, Ilich JZ, Skugor M, et al: Primary prevention of osteoporosis. Phys Med Rehab Clin North Am 6:595-627, 1995
21. Mansfield MJ, Rudlin CR, Crigler JF: Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty. J Clin Endocrinol Metab 66:3-8, 1988
22. Moll GW, Rosenfield RL, Fang FS: Administration of low dose estrogen rapidly and directly stimulates growth hormone production. Am J Dis Child 140:124-127, 1986
23. Margolis RN, Canalis E, Partridge NL: Anabolic hormones in bone: basic research therapeutic potential. J Clin Endocrinol Metab 81:872-877, 1996
24. Danesi L, Scacchi M, De-Martin M, et al: Evaluation of hypothalamic-pituitary function in patients with thalassemia major. J Endocrinol Invest 15:177-184, 1992
25. Saglamer L, Ulukutlu L, Ercan O, et al: Evaluation of growth hormone and insulin-like growth factor-I in prepubertal children with thalassemia. Turk J Pediatr 34:63-69, 1992
26. Pintor C, Cella SG, Manso P, et al: Impaired growth hormone (GH) response to GH-releasing hormone in thalassemia major. J Clin Endocrinol Metab 62:263-267, 1986
27. Leger J, Girot R, Crosnier H, et al: Normal growth hormone response to GH-releasing hormone in children with thalassemia major before puberty: A possible age-related effect. J Clin Endocrinol Metab 69:453-456, 1989
28. Shehadeh N, Hazani A, Rudolf MC, et al: Neurosecretory dysfunction of growth hormone secretion in thalassemia major. Acta Paediatr Scand 79:790-795, 1990
29. Katzos G, Harsoulis F, Papadopoulou M, et al: Circadian growth hormone secretion in short multitransfused prepubertal children with thalassemia major. Eur J Pediatr 154:445-449, 1995
30. Chatterjee R, Katz M, Cox T, et al: Evaluation of growth hormone in thalassemic boys with failed puberty: Spontaneous versus provocative test. Eur J Pediatr 152:721-726, 1993
31. Perignon F, Brauner R, Souberbielle JC: Growth and endocrine function in major thalassemia. Arch Francaises Pediatr 50:657-663, 1993
32. Postel-Vinay MC, Girot R, Hocquette JF: No evidence for a defect in growth hormone binding to liver membranes in thalassemia major. J Clin Endocrinol Metab 68:94-98, 1989
33. Unterman TG, Vasquez RM, Slas AJ, et al: Nutrition and somatomedin. XIII. Usefulness of somatomedin C in nutritional assessment. Am J Med 78:228-234, 1985
34. Ho KY, Veldhius JD, Johnson ML, et al: Fasting enhances growth hormone secretion and amplifies the complex rhythms of growth hormone secretion in man. J Clin Invest 81:968-975, 1988
35. Soliman AT, Hassan AI, Aref MK, et al: Serum insulin-like growth factor-I and II and growth hormone and insulin response to arginine infusion in children with protein-energy malnutrition before and after nutritional rehabilitation. Pediatr Res 20:1122-1130, 1986
36. Fuchs GJ, Tienboon P, Linpisarn S, et al: Nutritional factors and thalassemia major. Arch Dis Child 74:224-227, 1996
37. Gullo L, Corcioni E, Bria M, et al: Morphologic and functional evaluation of the exocrine pancreas in beta-thalassemia major. Pancreas 8:176-180, 1993
38. De Virgiliis S, Sanna G, Cornacchia I, et al: Serum ferritin, liver iron stores, and liver histology in children with thalassemia. Arch Dis Child 55:43-45, 1980
39. Bentham J, Rodriguez-Arnao J, Ross RJM: Acquired growth hormone resistance in patients with hypercatabolism. Horm Res 40:87-91, 1993
40. Soliman AT, ElBanna N, Ansari B: Growth hormone (GH) response to provocation, circulating insulin-like growth factor-I (IGF-I), and IGF-binding protein-3 concentrations, IGF-I generation test and clinical response to GH therapy in children with β-thalassemia. Eur J Endocrinol (in press)
41. Werther GA, Matthew RN, Burger HG, et al: Lack of response of nonsuppressible insulin-like activity to short-term administration of human growth hormone in thalassemia major. J Clin Endocrinol Metab 53:806-809, 1981
42. Low LC, Kwan EY, Lim YJ, et al: Growth hormone treatment of short Chinese children with beta-thalassemia major without growth hormone deficiency. Clin Endocrinol (oxf) 42:359-363, 1995
43. Brook CGD, Hindmarsh PC: The somatotropic axis in puberty. Endocrinol Metab Clin North Am 21:767-782, 1992
44. Aynsley Green A, Zachmann M, et al: Interrelation of the therapeutic effects of growth hormone and testosterone on growth in hypopituitarism. J Pediatr 89:992-997, 1976
45. Tanner JM, Whitehouse RH, Hughes PCR: Relative importance of growth hormone and sex steroids for the growth at puberty of trunk length, limb length and muscle width in growth hormone deficient children. J Pediatr 89:1000, 1976
46. Harris DA, Van Vliet G, Egli CA: Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinising hormone-releasing hormone agonist. J Clin Endocrinol Metab 61:152, 1985
47. Link K, Blizzard RM, Evans WS: The effect of androgens on the pulsatile release and the 24-hour mean concentration of GH in peripubertal males. J Clin Endocrinol Metab 62:159, 1986
48. Eakman GD, Dallas JS, Ponder S: The effects of testosterone and dihydrotestosterone on hypothalamic regulation of growth hormone secretion. J Clin Endocrinol Metab 81:1217-1223, 1996
49. Mansfield MJ, Rudlin CR, Crigler JR: Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty. J Clin Endocrinol Metab 66:3, 1988
50. Anonymous: Multicentre study on prevalence of endocrine complications in thalassemia major. Italian Working Group on Endocrine Complications in Non-endocrine Diseases. Clin Endocrinol (oxf) 42:581-586, 1995
51. Kletzky OA, Costin G, Marrs RP: Gonadotropin insufficiency in patients with thalassemia major. J Clin Endocrinol Metab 48:901-905, 1979
52. Bronspiegel-Weintrob N, Olivieri NF, Tyler B: Effect of age at the start of iron chelation therapy on gonadal function in B-thalassemia major. N Engl J Med 323:713-719, 1990
53. Borgna-Pignatti C, De Stefano P, Zonta L, et al: Growth and sexual maturation in thalassemia major. J Pediatr 106:150-155, 1985
54. Soliman AT, ElBanna N, AlSalmi I, et al: Insulin and glucagon responses to provocation with glucose and arginine in prepubertal children with thalassemia major before and after long-term blood transfusion. J Trop Pediatr 42:291-296, 1996
55. Lassman MN, Genel M, Wise JK, et al: Carbohydrate homeostasis and pancreatic islet cell function in thalassemia. Ann Intern Med 80:65-69, 1974
56. Merkel PA, Simonson DC, Ameil SA: Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 318:809-814, 1988
57. Vullo C, De Sanctis V, Katz M: Endocrine abnormalities in thalassemia. Ann NY Acad Sci 612:293-310, 1990
58. De Sanctis V, Zurlo MG, Senesi E: Insulin-dependent diabetes in thalassemia. Arch Dis Child 63:58-62, 1988
59. Carallo-Perinn P, Cassader M, Bozzo C: Mechanism of insulin resistance in human liver cirrhosis. J Clin Invest 75:1659-1665, 1985
60. Philips LS, Vasslopoulou-Sellin R: Somatomedins. N Engl J Med 302:371-376, 1980
61. Brismar K, Fernqvist-Forbes E, Wahren J, et al: Effect of insulin on the hepatic production of insulin-like growth factor-binding protein-1 (IGFBP-1), IGFBP3, and IGF-I in insulin dependent diabetes. J Clin Endocrinol Metab 79:872-878, 1994
62. Bereket A, Long CH, Blethen SL, et al: Effect of insulin on the insulin-like growth factor system in children with new-onset IDDM. J Clin Endocrinol Metab 80:1312-1317, 1995
63. Mohan S, Baylink DJ: Bone growth factors. Clin Orthop 263:30-48, 1991
64. Ebeling PR, Jones JD, O Fallon WM, et al: Short term effects of recombinant human insulin-like growth factor-I on bone turnover in normal women. J Clin Endocrinol Metab 77:1384-1387, 1993
65. Delany AM, Pash JM, Canalis E: Cellular and clinical perspectives on skeletal insulin like growth factor-I. J Cell Biochem 55:328-333, 1994
66. Tanaka H, Quarto R, Williams S, et al: In vivo and in vitro effects of insulin-like growth factor-I (IGF-I) on femoral mRNA expression in old rats. Bone 15:647-653, 1994
67. Narusawa K, Kakamura T, Suzaki K: The effects of recombinant human insulin-like growth factor (rhIGF)-I and rhIGF-I/IGF binding protein-3 administration on rat osteopenia induced by ovariectomy with concomitant bilateral sciatic neurectomy. J Bone Miner Res 10:1853-1864, 1995
68. Johansson AG, Forsulund A, Hambraeus L, et al: Growth hormone dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men. J Bone Miner Res 9:915-921, 1994
69. Junl A, Pedersen SA, Sorensen S, et al: Growth hormone (GH) treatment increases serum insulin-like growth factor binding protein-3, bone isoenzyme alkaline phosphatase and forearm bone mineral content in young adults with GH deficiency of childhood onset. Eur J Endocrinol 131:41-49, 1994
70. Blum WF, Albertsson-Wikland K, Rosberg S, et al: Serum levels of IGF-I and IGFBP3 reflect spontaneous GH secretion. J Clin Endocrinol Metab 76:1610-1616, 1993
71. Ghiron LJ, Thompson JL, Holloway L: Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. J Bone Miner Res 10:1844-1852, 1995
72. Lassman MN, O'Brien RT, Pearson HA, et al: Endocrine evaluation in thalassemia major. Ann NY Acad Sci 232:226-231, 1974
73. Newns GH: Endocrinopathies in thalassemia major. Acta Paediatr Scand 62:91-95, 1997
74. Overlaid F, Seshadri R: Hypoparathyroidism and other endocrine dysfunction complicating thalassemia major. Med J Aust 1:304-308, 1975
75. Masala AS, Gallisai D, Ginanni A: Parathyroid function and bone metabolism in children with beta thalassemia major: Effects of sex steroid treatment. Eur J Med 1:153-157, 1992
76. Gertner JM, Broadas AE, Anast CS, et al: Impaired parathyroid response to induced hypocalcemia in thalassemia major. J Pediatr 95:210-213, 1979
77. De Vernejoul MC, Girot R, Gueris J: Calcium-phosphate metabolism and bone disease in patients with homozygous thalassemia. J Clin Endocrinol Metab 54:276-281, 1982
78. Chow LH, Frei JV, Hodsman AB, et al: Low serum 25 hydroxyvitamin D in heriditary hemochromatosis: Relation to iron status. Gastroenterology 88:865-869, 1985
79. Monnier LH, Colette C, Ribot C, et al: Evidence for 25-hydroxy vitamin-D deficiency as a factor contributing to osteopenia in diabetic patients with idiopathic hemochromatosis. Eur J Clin Invest 10:183-187, 1980
80. De Vernejoul MC, Pointillart A, Golenzer CC: Effects of iron overload on bone remodeling in pigs. Am J Pathol 116:377-384, 1984
81. Diamond T, Steil D, Posen S: Osteoporosis in hemochromatosis: Iron excess, gonadal deficiency, or other factors? Ann Intern Med 110:430-436, 1989
82. Pawlotsky Y, Roussey M, Hany Y, et al: Hyperparathormone dans l'hemochromatose idiopathique. Nouv Presse Med 3:1757-1758, 1974
83. Manolagas SC, Jilka RL: Bone marrow, cytokines and bone remodeling. N Engl J Med 332:305-311, 1995
84. Mundy GR: Peptides and growth regulatory factors in bone. Rheum Dis Clin North Am 20:577-586, 1994
85. Pacifici R: Idiopathic hypercalciuria and osteoporosis - Distinct clinical manifestations of increased cytokine-induced bone resorption? J Clin Endocrinol Metab 82:29-31, 1997 (editorial)
86. Pacifici R: Estrogen, cytokines and pathogenesis of postmeno-pausal osteoporosis. J Bone Miner Res 11:251-257, 1996
87. Kimble RB, Matayoshi AB, Vannice JL: Simultaneous block of interleukin-1 and tumor-necrosis factor is required to completely prevent bone loss in the early post-ovariectomy period. Endocrinology 136:3054-3061, 1995
88. McIntosh N: Endocrinopathy in thalassemia major. Arch Dis Child 51:195-201, 1976
89. McIntosh N: Pituitary-adrenal function in thalassemia major. Arch Dis Child 48:653-657, 1973
90. Weintrob NB, Olivieri N, Tyler B, et al: Effect of age at the start of iron chelation therapy on gonadal function in B-thalassemia major. N Engl J Med 323:713-719, 1990
91. Costin G, Kogut MD, Hyman CB, et al: Endocrine abnormalities in thalassemia major. Am J Dis Child 133:497-502, 1997
92. L'Allemand D, Penhoat A, Lebrethon MC, et al: Insulin-like growth factors enhance steroidogenic enzyme and corticotropin receptor messenger ribonucleic acid levels and corticotropin steroidogenic responsiveness in cultured human adrenocortical cells. J Clin Endocrinol Metab 81:3892-3897, 1996
93. Pham-Huu-Trung MT, Villette JM, Bogyo A: Effects of insulin-like growth factor I (IGF-I) on enzymatic activity in human adrenocortical cells. Interactions with ACTH. J Steroid Biochem Mol Biol 39:903-909, 1991
94. L'Allemand D, Ardevol R, Penhoat A, et al: Role of insulin-like growth factors on androgen formation in human adrenocortical cells in culture: Secretion of IGF-I and its binding proteins. Horm Res 41:104, 1994 (abstr 191)
95. Khaw KT, Sneyd MJ, Compston J: Bone density, parathyroid hormone and 25-hydroxy vitamin-D concentrations in middle aged women. BMJ 305:273-277, 1992
96. Villareal DT, Civitelli R, Chines A: Subclinical vitamin-D deficiency in postmenopausal women with low vertebral bone mass. J Clin Endocrinol Metab 72:628-634, 1991
97. Oams ME, Roos JC, Bezemer PD: Prevention of bone loss by vitamin-D supplementation in elderly women: A randomized double blind trial. J Clin Endocrinol Metab 80:1052-1058, 1995
98. Bell NH: Vitamin-D metabolism, aging, and bone loss. J Clin Endocrinol Metab 80:1051, 1995 (editorial)
99. Johnston CC, Miller JZ, Slemenda CW: Calcium supplementation and increases in bone mineral density in children. N Engl J Med 327:82-87, 1992
100. Takahashi Y, Minamitani K, Kobayashi Y, et al: Spinal and femoral bone mass accumulation during normal adolescence: Comparison with female patients with sexual precocity and with hypogonadism. J Clin Endocrinol Metab 81:1248-1253, 1996
101. Dhuper S, Warren MP, Brooks-Gunn J, et al: Effects of hormonal status on bone density in adolescent girls. J Clin Endocrinol Metab 71:1083-1088, 1990
102. Keenan BS, Richards GE, Ponder SW, et al: Androgen-stimulated pubertal growth: The effects of testosterone and dihydrotestosterone on growth hormone and insulin-like growth factor-I in the treatment of short stature and delayed puberty. J Clin Endocrinol Metab 76:159, 1993